ANNOUNCEMENT NO. 297 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CEO Martin Helbo Behrens in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 ...

ANNOUNCEMENT NO. 294 9 October 2025 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter. At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2024/25 was approved, and the Board of Directors and the Executive Board were granted discharge. The Annual General Meeting approved the proposal of the Board of Dire ...

ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For 2025/26, ChemoMetec expects revenue in the range of DKK 545-565 million (2024/25: DKK 495.6 million) and EBITDA in the range of DKK 295-315 million (2024/25: DKK 258.0 million). The annual report for 2024/25, which is released along with this announcement, sets out the underlying assumptions a ...

Core Viewpoint - ChemoMetec expects to achieve revenue of approximately DKK 496 million for the financial year 2024/25, which is an increase from the previously estimated range of DKK 470-490 million [1]. Company Overview - ChemoMetec develops, manufactures, and markets instruments for cell counting and various other measurements, targeting the pharmaceutical, biotech, and agricultural industries globally [2]. - The company serves some of the world's leading pharmaceutical companies as its customers [2]. - ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen [3].